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Objective: To compare the acceptability, efficacy, adverse effects, and user satisfaction of the 
levonorgestrel intrauterine system (LNG-IUS) and trans-cervical resection of the endometrium 
(TCRE) for the treatment of menorrhagia.
Method: 104 women with menorrhagia were divided into 2 groups: 52 women had the   LNG-IUS 
inserted and 52 underwent TCRE. Menstrual pattern, pictorial blood loss assessment chart score, 
adverse effects, and rates of acceptability and satisfaction, were recorded at 6 and 12 months 
after the procedure.
Results: After a year there were reductions of 93.9% and 88.4% in menstrual blood loss in 
the TCRE and LNG-IUS groups, respectively. Amenorrhea was more common in the TCRE 
group and spotting and systemic effects in the LNG-IUS group. Satisfaction rates of the TCRE 
group were higher than the LNG-IUS group (80.8% vs 69.2%), but the difference was not 
statistically significant.
Conclusion: Although both treatments were found to be equally effective, LNG-IUS was less 
invasive and can be advised for younger women with a desire to preserve fertility.
Keywords: menorrhagia, trans-cervical endometrial resection, levonorgestrel-releasing 
  intrauterine system
Introduction
Menorrhagia constitutes a considerable problem for many women, causing discomfort, 
anxiety, and decreased quality of life. Menorrhagia is experienced by up to 30% of 
women of reproductive age and accounts for 60% of the general female population. It 
requires practice consultations for menstrual disorders and is the most common cause 
of iron deficiency anemia in healthy fertile women.1,2 Identifying new, less invasive, 
techniques, which are true alternatives to hysterectomy for treating menorrhagia, which 
would enable patients to resume their routine daily activities within a shorter period 
of time, represents a challenge to modern medicine.3,4
Medical management for dysfunctional uterine bleeding was, for a long time, 
hormonal therapy in the form of oral progesterone or the combined oral contraceptive 
pill. However, these methods have been revolutionized by newer modalities such as 
the levonorgestrel releasing intrauterine system (LNG-IUS: Mirena®, Schering AG, 
Berlin, Germany). LNG-IUS provides a non-surgical alternative treatment, which is 
reversible and spares fertility.5 Endometrial ablation continues to play an important 





ball ablation, hysteroscopic trans-cervical resection of the 
endometrium (TCRE) is still considered a gold standard.6 
In experienced hands, its complications are few but the 
operation requires hospitalization, and it is not suitable for 
women who want to preserve their fertility.
The aim of this study is to compare the efficacy, adverse 
effects, and rate of satisfaction and acceptability of   LNG-IUS 
and TCRE in the treatment of menorrhagia.
Materials and methods
One hundred and four women with menorrhagia were 
enrolled in the study. The patients were considered eli-
gible for the study if they were 35–45 years old, had heavy 
menstrual loss based on a pictorial blood assessment chart 
(PBAC) (score . 100) defined by Higham et al7 and with no 
history of medical treatment for at least 6 months before the 
trial. The exclusion criteria were: a previous history of deep 
venous thrombosis, thromboembolism, liver disease, pelvic 
disease, active genital tract infection, abnormal endometrial 
histology, abnormal cervical cytology, previous endometrial 
resection and ablation, or any other pathology such as uter-
ine prolapse or large myomas and pregnancy. Patients who 
were uncertain about their future wish for pregnancy were 
also excluded.
The patients were informed about both LNG-IUS and 
TCRE and allowed to choose either treatment in a series of 
sealed, opaque, sequentially numbered, envelopes prepared 
by an independent statistician, revealing the treatment code 
in a 1:1 individual randomization ratio. This was predeter-
mined by computer-generated random number tables, which 
were in balanced blocks of 20. Written informed consent was 
obtained from all patients.
Routine investigations included hemogram, liver, kidney 
and thyroid function tests, and gynecological examination 
included endometrial biopsy by Pipelle sampling and cervi-
cal smears to rule out endometrial or cervical neoplasia. 
A trans-vaginal ultrasound scan was also carried out on all 
patients to ensure that no fibroids were visible. The maximal 
anterior–posterior diameter of the uterus and endometrial 
thickness was recorded. In the TCRE group, the opera-
tion was performed under general anesthesia 5 weeks after 
endometrial preparation with a single injection of triptorelin 
3.76 mg and by a single operator. A Storz rigid resectoscope 
(Ch 26, model 27040 SL equipped with a Hopkins 27005 
B 300 optic; Storz Tuttlingen, Germany) with a 4-mm 
resection loop was passed into the uterine cavity. Glycine 
1.5% was infused for irrigation with an infusion pressure of 
100 mmHg. A mixed diathermy current of 120 W was used. 
The depth of resection varied from 4 to 6 mm, depending on 
the   preoperative endometrial preparation.
In LNG-IUS group, LNG-IUS was inserted within 7 days 
of the start of menstruation by a single gynecologist, based 
on the need for cervical dilatation on IUD insertion or not, 
which was classified as difficult or easy respectively. Any 
complications such as uterine perforation, hemorrhage, 
and abdominal cramps were recorded and the patients were 
observed for 1 hour before discharge. After the procedure, 
all patients were advised to keep a menstrual record includ-
ing length of menstrual cycles, days of bleeding, number 
of stained towels in one day, amount of staining and note 
any adverse effects namely spotting, abdominal cramps and 
pains, breast tenderness, headaches, acne, mood changes, 
and weight gain.
The patients were visited by a single physician in the outpa-
tient’s clinic 6 and 12 months posttreatment and the menstrual 
pattern of the preceding month and any adverse effects were 
noted. The primary outcomes included the menstrual pat-
tern namely amenorrhea and reduction in bleeding score. 
The secondary outcome was the rate of patient   satisfaction. 
“Amenorrhea” was defined as the absence of bleeding for at 
least 3 months, “no response” as continuous menorrhagia; 
and “regular cycles” when the bleeding occurred in an inter-
val between 25 and 32 days and the length of bleeding was 
not more than 5 days. Patient satisfaction was recorded on 
a scale of 1 to 5, with 1 being “least satisfied” and 5 being 
“most satisfied”. This clinical trial was approved by the Ethics 
Committee of Tehran University of Medical Sciences.
Statistical methods
A sample of 52 patients was divided into two groups 
according to the study by Gupta et al,11 in which a 97% and 
94% reduction in menstrual blood loss was reported in the 
LNG-IUS and TCRE groups, respectively, as well as dif-
ferences . 0.09 SD between the means of the two groups 
(quantitative variables), with a statistical power of 80% and 
a 95% confidence level.
Statistical analysis was performed using SPSS 16. Normal 
distribution of the data was verified using the Kolmogorov–
Smirnov test. The variables were described as mean and SD. 
The statistical differences between the groups were tested 
using Student’s unpaired t test, Mann–Whitney test, and Chi 
square test. Significance level was established as P , 0.05.
Results
One hundred and four women with menorrhagia were divided 
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52 underwent TCRE. The two groups were similar in age, 
BMI, PBAC score, and menstrual duration. However, the 
menstrual interval and duration of complaint were lower 
in TCRE group (Table 1). The previous treatment of the 
two groups had been similar, and endometrial histology of 
most patients showed secretory endometrium. Endometrial 
thickness in LNG-IUS was 8.60 ± 4.5 and in TCRE was 
8.41 ± 4.4 (P = 0.88).
Twelve patients had systematic disorders including two 
patients with coagolopathy due to warfarin use in TCRE 
group (3.8%), three (5.8%) with diabetes, three (5.8%) with 
hypothyroidism, and two (3.8%) with corticotrophin-releas-
ing factor (CRF) in each group. In the LNG-IUS group, two 
patients required cervical dilatation but there were no uterine 
perforations or cervical injury. All patients were discharged 
within 1 hour of the procedure. In TCRE group one case of 
uterine perforation with no hemorrhagic complication needed 
intervention. This patient was hospitalized for 1 day after 
TCRE. Of the remaining patients, one who had diabetes was 
observed for 48 hours post-procedure, but the others were 
discharged the same day. Because we had no access to twelve 
of the patients in the 12 months after the procedure for follow 
up, they were excluded from the trial (Figure 1). The pictorial 
bleeding score was significantly decreased at 6 and 12 months 
post-procedure in the two groups (P , 0.0001) and was sta-
tistically similar between the 2. PBAC score after 6 months 
was 70.65 ± 115.61 and 60.38 ± 110.65 in the TCRE and 
LNG-IUS groups respectively. There was 44.7% amenorrhea 
in the TCRE group compared with 11.1% in the LNG-IUS 
group (P , 0.0001, difference 33.6%, 80% CI 15%–52%). 
The rate of no response to treatment was 4.2% in the TCRE 
group compared with 20% in the LNG-IUS group (P = 0.007, 
difference 15.8%, 80% CI 3%–29%) (Table 2).
In TCRE group, one patient had uterine perforation and 
there were two cases of hematometra due to cervical   stenosis 
which were released by cervical dilation. Two patients under-
went hysterectomy for persistent menorrhagia in the 12th 
month post-procedure. In LNG-IUS group, nine patients 
reported expulsion of IUS and in six patients it was removed 
(five for continued menorrhagia and one for unacceptable 
spotting and weight gain). Six patients (12.7%) reported 
spotting. The adverse effects of LNG-IUS were cramps and 
pains in four (8.2%), spotting in 19 (38.8%), breast tender-
ness in ten (20.4%), headaches in nine (18.4%), acne in two 
(4.1%), mood changes in four (8.2%), weight gain in one 
(2%) and ovarian cyst in one (2%) patient. Satisfaction score 
of more than three was achieved in 42 patients (80.8%) and 
36 patients (69.2%) of TCRE and LNG-IUS groups respec-
tively and satisfaction score of less than three was recorded 
for seven patients (10.4%) and 16 patients (30.8%) of TCRE 
and LNG-IUS groups respectively. Mean satisfaction score 
was similar in the two groups (P = 0.43) (Table 2).
Discussion
Heavy menstrual bleeding is a significant health problem 
that impairs the quality of life. The perception of heavy 
bleeding is highly subjective, however, and management of 
the condition usually depends on both the amount of bleed-
ing and the degree of discomfort found acceptable by the 
individual woman.
Hysterectomy was once the only surgical option for heavy 
menstrual bleeding, and almost half of the hysterectomies 
currently performed worldwide are carried out for this rea-
son, but it is a major surgical intervention associated with 
surgical risks and substantial costs.8 Endometrial destruction 
techniques, which aim to destroy or remove the endometrial 
tissue, include roller-ball ablation and trans-cervical resection 
under direct hysteroscopic vision and second generation non-
hysteroscopic techniques.9 LNG-IUS provides a nonsurgical 
alternative, which is reversible and spares fertility.10
Table  1  Baseline  characteristics  (with  percentages  rounded 
for clarity)





Age (years) 40.2 ± 4.3 41.5 ± 4.4 0.14
BMI (kg/m2) 28.3 ± 4.2 26.7 ± 3.3 0.07
Duration of complaint (years) 3.35 ± 0.32 2.07 ± 0.27 0.03
Bleeding duration (day) 10.1 ± 4.2 14.5 ± 9.2 0.071*
PBAc score   595 ± 165   596 ± 185 0.069*
Menstrual interval (days) 25.6 ± 4.7 21.7 ± 6.6 0.005
Notes: Values are given as mean ± sD; *Mann–Whitney test.
Abbreviations:  BMI,  body  mass  index;  LnG-IUs,  levonorgestrel  intrauterine 
system;  PBAc,  pictorial  blood  loss  assessment  score;  Tcre,  trans-cervical 
resection of the endometrium.
Table 2 The satisfaction and acceptability, menstrual status and 






Amenorrhea 5 (11.1) 21 (44.7) ,0.0001
normal menses or  
hypo menorhea
31 (68.8) 24 (51.1) 0.08
no response to treat 9 (20) 2 (4.24) 0.02
Difference in bleeding score 526.8 ± 148.0 560.2 ± 177.9 0.335
Mean of satisfaction 3.08 ± 1.26 2.5 ± 1.59 0.43
Notes: Decreased number of patients is due to having no access to patients for 
follow up; values are given as mean ± sD or n (%).
Abbreviations: LnG-IUs, levonorgestrel intrauterine system; Tcre, trans-cervical 


















follow up at 1 year
45 patients completed
follow up at 1 year
Figure 1 Flow diagram of the trial.
Abbreviations: LnG-IUs, levonorgestrel intrauterine system; Tcre, trans-cervical 
resection of the endometrium.
The results of this study demonstrate that both LNG-IUS 
and TCRE clearly reduce menstrual blood loss. Responses to 
treatment at the end of 1 year follow up showed no significant 
difference between the two groups (93.9% for TCRE and 
88.4% for LNG-IUS), but the rate of amenorrhea in the TCRE 
group was higher (P , 0.0001). In the study by Gupta et al,11 
97% and 94% reductions were observed in menstrual blood 
loss in the LNG-IUS and TCRE groups respectively. However, 
Crosignani et al and Istre and Trolle reported a significantly 
higher reduction in menstrual blood loss with TCRE than 
with LNG-IUS insertion.12,13 Based on the meta-analysis of 
six randomized clinical trials, the efficacy of the LNG-IUS 
in the management of heavy menstrual bleeding appears to 
have similar therapeutic effects to that of endometrial abla-
tion up to 2 years after treatment.14 In our study, amenorrhea 
was more common in the TCRE group than in LNG-IUS 
at 12 months posttreatment (44.7% vs 11.1% respectively) 
and spotting was more common in LNG-IUS group (38% vs 
12%). In Hidalgo et al, 44% of the women who had LNG-
IUS inserted reported amenorrhea at the 6th month of use. 
This rate maintained stability in 50% of these women after 12 
and 24 months of use and spotting was present in 25% of the 
users at 6 months, decreasing to 11% at 24 months. This rate 
maintained stability at 50% after 12 and 24 months of use.15 
Wide dissemination of information on the expected bleeding 
patterns after LNG-IUS insertion is necessary, so that it can 
reduce unnecessary, more radical, surgery.
In our study, similar to that of Gupta et al, the systemic 
effects such as breast tenderness, acne, mood changes, head-
aches, and bloating were more common in LNG-IUS group 
than TCRE group and the most common side effect in LNG-
IUS group was spotting.10 In de Souza et al, both the LNG-IUS 
and thermal balloon ablation appear to be effective in control-
ling heavy menstrual bleeding, although post treatment uterine 
bleeding patterns may vary between the 2 methods.16
Satisfaction rates of TCRE group in our study were 
higher than in LNG-IUS group (80.8% vs 69.2%) but their 
difference was not statistically significant. A meta-analysis 
of heavy menstrual bleeding treatment stated that at around 
12 months posttreatment, both first- and second-generation 
endometrial destruction techniques were associated with 
greater dissatisfaction than hysterectomy, although rates 
were low for all treatments. Absolute differences were small 
compared with endometrial destruction and LNG-IUS. There 
was comparable efficacy, although studies of LNG-IUS were 
generally small and consequently imprecise.17 The results of 
our study clearly demonstrate that both LNG-IUS and TCRE 
clearly reduce menstrual blood loss and their satisfaction rate 
is similar. Also in our study, twelve patients with a systemic 
disorder such as coagolopathy and CRF responded to the 
treatment as well as others.
Several trials have compared the two modalities, but to 
our knowledge the present study is the second of its kind 
conducted in an Islamic country. In the religion of Islam, 
prolonged bleeding or spotting is a problem for performing 
religious activities (eg, such women are not allowed to say 
prayers or fast) and consequently affects patient quality of life. 
The results of another study in Egypt were similar to ours.18
Perhaps one of the biggest limitations of our study was 
the likeliness that patients would choose to undergo LNG-
IUS rather than TCRE, after becoming informed about 
these treatments. Regarding the efficacy of LNG-IUS in the 
medical management of dysfunctional uterine bleeding that 
is similar to endometrial resection, this treatment can be used 
as first- or second-line option for the medical management 
of dysfunctional uterine bleeding and due to its reversibility 
and contraceptive effect, it may become a first-line treatment 
for younger patients especially in developing countries where 
resources and experiences of operative hysteroscopy are 
limited. In addition, the cost of TCRE is almost 3 times that 
of LNG-IUS in Iran (US$300 vs US$120).
Conclusion
The LNG-IUS is a contraceptive device that has dramatic 
effects in lowering bleeding intensity in menorrhagia. It is International Journal of Women’s Health
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further characterized by reversibility and may be the   first-line 
treatment in younger women with menorrhagia. Due to its low 
systemic steroidal dose, the adverse events are mild and few. 
Although TCRE is even more effective in reducing blood 
loss, it is irreversible and needs operative facilities. Overall, 
the tolerability of both treatments is good. The findings of this 
study can guide gynecologists and hospital administrators in 
choosing the appropriate treatment method for menorrhagia.
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